|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 3005-3014.
Prepublished online as a Blood First Edition Paper on September 20, 2007; DOI 10.1182/blood-2007-03-079368.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
The molecular signature of MDS stem cells supports a stem-cell origin of 5q– myelodysplastic syndromes
Lars Nilsson1,
Patrik Edén2,
Eleonor Olsson3,
Robert Månsson1,
Ingbritt Åstrand-Grundström1,
Bodil Strömbeck4,
Kim Theilgaard-Mönch5,
Kristina Anderson1,
Robert Hast6,
Eva Hellström-Lindberg7,
Jan Samuelsson8,
Gösta Bergh9,
Claus Nerlov1,10,
Bertil Johansson4,
Mikael Sigvardsson1,
Åke Borg3, and
Sten Eirik W. Jacobsen1
1 Hematopoietic Stem Cell Laboratory, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund, Sweden;
2 Complex Systems Division, Department of Theoretical Physics, Lund University, Lund, Sweden;
3 DNA Microarray Resource Center, Department of Oncology, Lund University, Lund, Sweden;
4 Department of Clinical Genetics, Lund University, Lund, Sweden;
5 Granulocyte Research Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
6 Hematology Center, Karolinska University Hospital, Stockholm, Sweden;
7 Department of Medicine, Division of Hematology, Karolinska University Hospital (Huddinge), Stockholm, Sweden;
8 Department of Medicine, South Hospital, Karolinska Institute, Stockholm, Sweden;
9 Department of Medicine, Helsingborg Hospital, Sweden; and
10 European Molecular Biology Laboratory (EMBL), Mouse Biology Unit, Monterotondo, Italy
Global gene expression profiling of highly purified 5q-deleted CD34+CD38–Thy1+ cells in 5q– myelodysplastic syndromes (MDSs) supported that they might originate from and outcompete normal CD34+CD38–Thy1+ hematopoietic stem cells. Few but distinct differences in gene expression distinguished MDS and normal stem cells. Expression of BMI1, encoding a critical regulator of self-renewal, was up-regulated in 5q– stem cells. Whereas multiple previous MDS genetic screens failed to identify altered expression of the gene encoding the myeloid transcription factor CEBPA, stage-specific and extensive down-regulation of CEBPA was specifically observed in MDS progenitors. These studies establish the importance of molecular characterization of distinct stages of cancer stem and progenitor cells to enhance the resolution of stage-specific dysregulated gene expression.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. R. Geest, M. Buitenhuis, E. Vellenga, and P. J. Coffer
Ectopic expression of C/EBP{alpha} and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia
Haematologica,
August 1, 2009;
94(8):
1075 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Majeti, M. W. Becker, Q. Tian, T.-L. M. Lee, X. Yan, R. Liu, J.-H. Chiang, L. Hood, M. F. Clarke, and I. L. Weissman
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
PNAS,
March 3, 2009;
106(9):
3396 - 3401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Starczynowski, S. Vercauteren, A. Telenius, S. Sung, K. Tohyama, A. Brooks-Wilson, J. J. Spinelli, C. J. Eaves, A. C. Eaves, D. E. Horsman, et al.
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
Blood,
October 15, 2008;
112(8):
3412 - 3424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. J. Chung, C. W. Choi, C. Slape, T. Fry, and P. D. Aplan
Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell
PNAS,
September 16, 2008;
105(37):
14088 - 14093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Nimer
MDS: A Stem Cell Disorder--But What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease?
Hematology,
January 1, 2008;
2008(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
